Sotalol Hcl
Brand names: Betapace, Betapace Af, Sotalol, Sotalol Af, Sotylize
At a glance
- Medicare prescriptions, 2024
- 836,069
- Medicare drug cost
- $16.7M
- Average cost per prescription
- $20.02
- Clinicians who prescribed it
- 21,006
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
1. INDICATIONS AND USAGE Sotalol/Sotalol AF is an antiarrhythmic indicated for: • the treatment of life-threatening ventricular arrhythmias • the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) Limitations of Use • Sotalol has not been shown to enhance survival in patients with life threatening ventricular arrhythmias • Avoid use in patients with minimally symptomatic or easily reversible AFIB/AFL 1.1 Life-Threatening Ventricular Arrhythmias Sotalol/Sotalol
From the FDA-approved prescribing information (label dated April 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: LIFE THREATENING PROARRHYTHMIA To minimize the risk of drug-induced arrhythmia, initiate or reinitiate oral sotalol in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring. Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug. Calculate creatinine clearance to determine appropriate dosing. WARNING: LIFE THREATENING PROARRHYTHMIA See full prescribing information for complete boxed warning. • Sotalol/Sotalol AF can cause life-threatening ventricular tachycardia associated with QT interval prolongation. • If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug. • Initiate or reinitiate in a facility that…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Cardiology 31.8%
- Cardiac Electrophysiology 19.5%
- Nurse Practitioners 17.6%
- Interventional Cardiology 10.7%
- Family Medicine 6.7%
- Internal Medicine 6.7%
- Physician Assistants 5.2%
- Geriatric Medicine 0.5%
- Heart Failure & Transplant Cardiology 0.3%
- General Practice 0.2%
- Hospitalist 0.2%
- Nuclear Medicine 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 10% from 2019 to 2024.
Biggest change by state since 2019
- Idaho +25%
- Minnesota +17%
- Washington +12%
- Arizona +8%
- Arkansas +6%
- Pennsylvania (smallest change) −23%
- South Carolina (smallest change) −23%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 80 mg | blue oval tablet, 12 mm, scored to split in 2 | 841 O |
| 120 mg | blue oval tablet, 14 mm, scored to split in 2 | 842 O |
| 160 mg | blue oval tablet, 15 mm, scored to split in 2 | 843 O |
| 240 mg | blue oval tablet, 18 mm, scored to split in 2 | 844 O |
Unichem Pharmaceuticals (USA), Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 80 mg | blue capsule, 12 mm, scored to split in 2 | B104 |
| 80 mg | white capsule, 12 mm, scored to split in 2 | B107 |
| 120 mg | blue capsule, 14 mm, scored to split in 2 | B105 |
| 120 mg | white capsule, 14 mm, scored to split in 2 | B108 |
| 160 mg | blue capsule, 15 mm, scored to split in 2 | B106 |
| 160 mg | white capsule, 15 mm, scored to split in 2 | B109 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.